Business Expansion: Global Activated Partial Thromboplastin Time Test Market Projected to Surpass $601.2 Million, Growing at 6.8% CAGR from 2019 to 2026 [230-Pages] |Confirmed By Research Dive

The global activated partial thromboplastin time test market is projected to experience remarkable growth in the upcoming years. Rising advancements and improvements by market players in activated partial thromboplastin time tests is fueling the growth of the market. The point-of-care testing sub-segment and instruments sub-segment are estimated to lead the market. The Asia-Pacific market is projected to observe significant growth.


New York, USA, May 04, 2022 (GLOBE NEWSWIRE) -- A new report on the global activated partial thromboplastin time test market has been added by Research Dive to its repository. As per the report, the market is expected to garner $601.2 million by 2026, growing at a CAGR of 6.8% from 2019 to 2026. This report provides thorough insights into the present condition and future outlook of the global industry. The report is drafted by professional market analysts and assures to be a reliable source of data and detailed market insights for new players, investors, prevailing market players, stakeholders, shareholders, etc.

Factors Impacting the Market Growth:

Rising demand for activated partial thromboplastin time testing devices in medical organizations is fueling the growth of the global activated partial thromboplastin time test market. Furthermore, growing advancements and improvements by market players in activated partial thromboplastin time tests is projected to give rise to profitable opportunities for the market growth during the forecast period. However, high costs of test devices is anticipated to hinder the market growth.

The report segments the global activated partial thromboplastin time test market into product type, end use, and region.

Download a PDF Sample of the Activated Partial Thromboplastin Time Test (aPTTT) Market (Including Tables, TOC, and Figures

Instruments Sub-Segment to Experience Remarkable Growth

Among the product type segment, the instruments sub-segment is expected to experience significant growth with a CAGR of 7.2% during the forecast period. The growth of this sub-segment is mostly because of the growing focus of manufacturers on enhancing future generation of instruments for medical diagnosis by improving productivity, precision, and overall performance at a minimal treatment cost.

Point-of-care Testing Sub-Segment to Observe Noteworthy Growth

Among the end use segment, the point-of-care testing sub-segment of the activated partial thromboplastin time test market is projected to grow with 7.7% CAGR during the estimated timeframe. This is mostly because rising number of point-of-care testing diagnosis centers worldwide.

Asia-Pacific Region to Witness Remarkable Growth

The report analyzes the global activated partial thromboplastin time test market across several regions such as Asia-Pacific, Europe, Asia Pacific, and LAMEA. Among these, the Asia-Pacific region market is expected to grow significantly and garner $143.1 million during the estimated timeframe. The growth of this region market is mainly owing to the rising developments in the healthcare sector in the region.

How COVID -19 Pandemic has Positive Growth for Activated Partial Thromboplastin Time Test (aPTTT) Market? Get in Touch with our Expert

Major Players in the Market:

The report lists some of the leading players functioning in the global activated partial thromboplastin time test market including

  1. Danaher
  2. bioMérieux, Inc.
  3. Bio-Rad Laboratories, Inc.
  4. HORIBA, Ltd.
  5. Siemens Healthcare Private Limited
  6. Hoffmann-La Roche Ltd
  7. Takara Bio Inc.
  8. ThermoFisher
  9. Ortho Clinical Diagnostics
  10. Beckman Coulter, Inc.
  11. Abbott.

The report also offers several industry-top tactics and approaches such as top strategic moves & developments, product/service range, business performance, Porter five forces analysis, and SWOT analysis of the foremost players, functioning in the global industry. For instance, in December 2018, Sysmex, a company focused on offering health services with diagnostic solutions that alter the future of healthcare and contribute to healthier lives, launched Revohem FIX Chromogenic, a Blood Coagulation Factor IX measurement kit by using Chromogenic Assay, to help in the diagnoses and assistance of the treatment of Hemophilia B.

Get the Customized report on the Activated Partial Thromboplastin Time Test (aPTTT) Market & Avail 10%OFF

Some Trending Article Links:

 

Coordonnées